{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:40:13Z","timestamp":1787614813900,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":3660,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.7861\/clinmedicine.14-2-165","type":"journal-article","created":{"date-parts":[[2014,4,8]],"date-time":"2014-04-08T06:07:33Z","timestamp":1396937253000},"page":"165-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The newer direct oral anticoagulants: a practical guide"],"prefix":"10.1016","volume":"14","author":[{"given":"Jecko","family":"Thachil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.7861\/clinmedicine.14-2-165_bib1","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib14","series-title":"Pradaxa 110\u00a0mg hard capsules: summary of product characteristics","year":"2013"},{"key":"10.7861\/clinmedicine.14-2-165_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11239-013-0967-z","article-title":"The pharmacology of novel oral anticoagulants","volume":"37","author":"Dewald","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"10.7861\/clinmedicine.14-2-165_bib16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bjh.12502","article-title":"Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban","volume":"163","author":"Baglin","year":"2013","journal-title":"Br J Haematol"},{"key":"10.7861\/clinmedicine.14-2-165_bib17","series-title":"Xarelto 10\u00a0mg film-coated tablets: summary of product characteristics","year":"2014"},{"key":"10.7861\/clinmedicine.14-2-165_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.7861\/clinmedicine.14-2-165_bib19","series-title":"Eliquis 2.5\u00a0mg film-coated tablets: summary of product characteristics","year":"2013"},{"key":"10.7861\/clinmedicine.14-2-165_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12325-012-0026-8","article-title":"Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban","volume":"29","author":"Potpara","year":"2012","journal-title":"Adv Ther"},{"key":"10.7861\/clinmedicine.14-2-165_bib21","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/CIRCULATIONAHA.112.115410","article-title":"Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature","volume":"126","author":"Dentali","year":"2012","journal-title":"Circulation"},{"key":"10.7861\/clinmedicine.14-2-165_bib22","doi-asserted-by":"crossref","first-page":"e","DOI":"10.1136\/bmj.e7498","article-title":"Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials","volume":"345","author":"Fox","year":"2012","journal-title":"BMJ"},{"key":"10.7861\/clinmedicine.14-2-165_bib23","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.7861\/clinmedicine.14-2-165_bib24","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.7861\/clinmedicine.14-2-165_bib25","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJMp1302834","article-title":"Dabigatran and postmarketing reports of bleeding","volume":"368","author":"Southworth","year":"2013","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib26","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u201creal world\u201d patients with atrial fibrillation: a prospective nationwide cohort study","volume":"61","author":"Larsen","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.7861\/clinmedicine.14-2-165_bib27","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.19.19","article-title":"Management and outcomes of major bleeding on dabigatran or warfarin","volume":"120","author":"Majeed","year":"2012","journal-title":"Blood"},{"key":"10.7861\/clinmedicine.14-2-165_bib28","doi-asserted-by":"crossref","DOI":"10.1378\/chest.1388403","article-title":"Incidence and outcomes of gastrointestinal haemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: results from the ROCKET AF trial","volume":"142","author":"Nessel","year":"2012","journal-title":"Chest"},{"key":"10.7861\/clinmedicine.14-2-165_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1160\/TH13-02-0150","article-title":"Gastrointestinal bleeding with the new oral anticoagulants \u2013 defining the issues and the management strategies","volume":"110","author":"Desai","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.7861\/clinmedicine.14-2-165_bib30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.gie.2013.04.179","article-title":"Novel oral anticoagulants in gastroenterology practice","volume":"78","author":"Desai","year":"2013","journal-title":"Gastrointest Endosc"},{"key":"10.7861\/clinmedicine.14-2-165_bib31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events meta-analysis of noninferiority randomized controlled trials","volume":"172","author":"Uchino","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.beha.2013.07.008","article-title":"Novel oral anticoagulants in non-valvular atrial fibrillation","volume":"26","author":"Potpara","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"issue":"Suppl 1","key":"10.7861\/clinmedicine.14-2-165_bib33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/jth.12227","article-title":"The role of the laboratory in treatment with new oral anticoagulants","volume":"11","author":"Baglin","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.7861\/clinmedicine.14-2-165_bib34","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1111\/j.1538-7836.2010.04057.x","article-title":"Monitoring new oral antithrombotics: what we should know before we can decide","volume":"8","author":"Al Dieri","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.7861\/clinmedicine.14-2-165_bib35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH10-06-0342","article-title":"Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays","volume":"105","author":"Lindahl","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.7861\/clinmedicine.14-2-165_bib36","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MBC.0b013e32834f1b0c","article-title":"Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran","volume":"23","author":"Stangier","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.7861\/clinmedicine.14-2-165_bib37","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/bjh.12173","article-title":"Normal prothrombin time in the presence of therapeutic levels of rivaroxaban","volume":"160","author":"van Veen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.7861\/clinmedicine.14-2-165_bib38","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.12566","article-title":"Correlating prothrombin time with plasma rivaroxaban level","volume":"163","author":"Rodgers","year":"2013","journal-title":"Br J Haematol"},{"key":"10.7861\/clinmedicine.14-2-165_bib39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1160\/TH11-06-0391","article-title":"Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls","volume":"107","author":"Samama","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.7861\/clinmedicine.14-2-165_bib40","doi-asserted-by":"crossref","first-page":"e","DOI":"10.1345\/aph.1Q105","article-title":"Potential inaccuracy of point-of-care INR in dabigatran-treated patients","volume":"45","author":"Baruch","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.7861\/clinmedicine.14-2-165_bib41","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jth.12149","article-title":"Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","volume":"11","author":"Baglin","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.7861\/clinmedicine.14-2-165_bib42","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc1112874","article-title":"Bleeding risk with dabigatran in the frail elderly","volume":"366","author":"Harper","year":"2012","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/0091270011415527","article-title":"Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment","volume":"52","author":"Hariharan","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.7861\/clinmedicine.14-2-165_bib44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.7861\/clinmedicine.14-2-165_bib45","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur Heart J"},{"key":"10.7861\/clinmedicine.14-2-165_bib46","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","article-title":"European Heart Rhythm Association practical guide on the use of new oral -anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","author":"Heidbuchel","year":"2013","journal-title":"Europace"},{"key":"10.7861\/clinmedicine.14-2-165_bib47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.111.090464","article-title":"Periprocedural bleeding and thromboembolic events with dabigatran compared with -warfarin: results from the randomized evaluation of longterm -anticoagulation therapy (RE-LY) randomized trial","volume":"126","author":"Healey","year":"2012","journal-title":"Circulation"},{"key":"10.7861\/clinmedicine.14-2-165_bib48","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1160\/TH12-11-0868","article-title":"The perioperative management of new direct oral anticoagulants: a question without answers","volume":"110","author":"Ferrandis","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.7861\/clinmedicine.14-2-165_bib49","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"Van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.7861\/clinmedicine.14-2-165_bib50","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy -subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.7861\/clinmedicine.14-2-165_bib51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/bjh.12107","article-title":"Guideline on the management of bleeding in patients on antithrombotic agents","volume":"160","author":"Makris","year":"2013","journal-title":"Br J Haematol"},{"key":"10.7861\/clinmedicine.14-2-165_bib52","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7326\/0003-4819-157-10-201211200-00532","article-title":"Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review","volume":"157","author":"Adam","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib53","doi-asserted-by":"crossref","first-page":"275","DOI":"10.7326\/0003-4819-159-4-201308200-00008","article-title":"Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review","volume":"159","author":"Adam","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib54","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.7861\/clinmedicine.14-2-165_bib55","doi-asserted-by":"crossref","first-page":"653","DOI":"10.7326\/0003-4819-155-10-201111150-00003","article-title":"Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial","volume":"155","author":"Schulman","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib56","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/jth.12140","article-title":"Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary","volume":"11","author":"Lip","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.7861\/clinmedicine.14-2-165_bib57","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/jth.12241","article-title":"Adherence to anticoagulant treatment with dabigatran in a real-world setting","volume":"11","author":"Schulman","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.7861\/clinmedicine.14-2-165_bib58","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10928-007-9058-0","article-title":"Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics","volume":"34","author":"Comt\u00e9","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.7861\/clinmedicine.14-2-165_bib4","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib6","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib7","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib10","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.jacc.2013.01.066","volume":"61","author":"Mega","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.7861\/clinmedicine.14-2-165_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.14-2-165_bib13","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824028112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824028112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmedicine.14-2-165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:38:10Z","timestamp":1761460690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824028112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1470211824028112"],"URL":"https:\/\/doi.org\/10.7861\/clinmedicine.14-2-165","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The newer direct oral anticoagulants: a practical guide","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmedicine.14-2-165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2014. All rights reserved.","name":"copyright","label":"Copyright"}]}}